The pharmaceutical industry makes, finds, develops, and sells pharmaceutical products or medicines for the purpose to heal them, treat them, or relieve the symptoms associated with a disease. Pharmaceutical companies can produce both pharmaceutical drugs and generic or brand drugs. Generic drugs are chemically-lookalized versions of patented drugs. It is not surprising that we use so many pharmaceutical products to address common diseases like diabetes, hypertension, and asthma.
Biotechnology has emerged as a relatively new term in the last few decades. It refers to the application of science to the manufacture of pharmaceuticals. It began as a small industry focused on developing and researching genetically engineered crops and animals. Recently, the FDA has approved the production of genetically engineered crops, and now pharmaceutical corporations are working on similar genetically altered crops for animal feed. The move by the FDA to regulate these crops as drugs may spur the production of pharmaceuticals based on genetically engineered crops.
Another trend seen in the area of pharmaceuticals is the development and manufacture of drugs intended to fight cancer. There have been numerous drug discoveries in recent years that are being developed to attack cancer. Some of the latest cancer drugs include amitriptyline, which is being studied as a treatment for leukemia and mesothelioma. Recently, another anti-cancer drug called Gleevec was approved by the FDA for its ability to kill cancer cells.
Biotechnological plants often specialize in the manufacture of generic products to address minor diseases that are easy to produce at low cost. Examples of such pharmaceuticals include allergy medicine Glucophage (GNC) and its generic products, ivermectin, Advair, and generic glucocorticoids, such as Indocin, Froval, and Mavik. Biotechnological companies are also focusing on the manufacture of pharmaceuticals to address chronic diseases that are difficult to treat with chemical compounds. Biotechnological companies are experimenting on methods to produce vaccines and other medications that can prevent or cure common diseases such as lupus, diabetes, and autism. These companies are also exploring the production of insulin for the purpose of controlling blood glucose in patients with diabetes.
There is a promising future for pharmaceuticals and biotechnology alike, with both industries focused on the development of useful medications. However, in terms of the FDA’s recent decision, there is an increased likelihood of Food and Drug Administration regulation and changes in clinical guidelines. For example, it is likely that clinical guidelines for the treatment of Alzheimer’s disease will shift towards the use of medications based on DNA engineering. Additionally, the FDA will likely request pharmaceutical firms carry out genetic modifications of drugs that are designed to treat cancer. Lastly, it is not clear how the FDA will react to generic products that contain genes that have been inserted into them.
The advancement of biotechnology has led to the discovery of many medicines and medical devices that are more efficient, safer, and less harmful to humans. However, given the rapid pace of technology, pharmaceutical companies must remain vigilant to ensure that the company releases only effective medicines. In the case of Alzheimer’s disease, for example, biotechnology companies are developing drugs that can prevent the onset of Alzheimer’s disease, while also improving the patient’s cognitive abilities. The introduction of these effective medicines is only possible through the cooperation between the pharmaceutical companies and biotechnology industries. Both parties share the goal of ensuring that the public gets access to only safe and effective medicines